BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CBG002 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of CBG002\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06705725-3414@assetmemo.bio
DTSTAMP:20261121T004539Z
DTSTART;VALUE=DATE:20271025
DTEND;VALUE=DATE:20271026
SUMMARY:CBG002: Phase 1 readout est. (NCT06705725)
DESCRIPTION:CBG002\, phase 1\, Multiple Myeloma.\nStudy: Phase I Clinical S
 tudy of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Mye
 loma\nEstimated primary completion: 25 October 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/cbg002#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06705725
URL:https://assetmemo.bio/drug/cbg002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
